CN1198614C - pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 - Google Patents

pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 Download PDF

Info

Publication number
CN1198614C
CN1198614C CNB988063891A CN98806389A CN1198614C CN 1198614 C CN1198614 C CN 1198614C CN B988063891 A CNB988063891 A CN B988063891A CN 98806389 A CN98806389 A CN 98806389A CN 1198614 C CN1198614 C CN 1198614C
Authority
CN
China
Prior art keywords
people
inh
lps
cell
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988063891A
Other languages
English (en)
Chinese (zh)
Other versions
CN1261278A (zh
Inventor
E·昆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octamer Inc
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/855,616 external-priority patent/US5908861A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of CN1261278A publication Critical patent/CN1261278A/zh
Application granted granted Critical
Publication of CN1198614C publication Critical patent/CN1198614C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB988063891A 1997-05-13 1998-05-13 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法 Expired - Fee Related CN1198614C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/855,616 1997-05-13
US08/855,616 US5908861A (en) 1997-05-13 1997-05-13 Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US09/056,396 1998-04-06
US09/056,396 US6303629B1 (en) 1997-05-13 1998-04-06 Methods for treating inflammation, inflammatory diseases, arthritis and stroke using pADPRT inhibitors

Publications (2)

Publication Number Publication Date
CN1261278A CN1261278A (zh) 2000-07-26
CN1198614C true CN1198614C (zh) 2005-04-27

Family

ID=26735288

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988063891A Expired - Fee Related CN1198614C (zh) 1997-05-13 1998-05-13 pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法

Country Status (9)

Country Link
EP (1) EP1009404A4 (ja)
JP (1) JP4362638B2 (ja)
CN (1) CN1198614C (ja)
AU (2) AU7484798A (ja)
BR (1) BR9809115A (ja)
CA (1) CA2289119C (ja)
IL (1) IL132758A0 (ja)
NZ (1) NZ501650A (ja)
WO (2) WO1998051307A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1538A (en) 1999-01-11 2006-01-10 Agouron Pharma Tricyclic inhibitors of poly (adp-ribose) polymerases.
ECSP003637A (es) 1999-08-31 2002-03-25 Agouron Pharma Inhibidores triciclicos de poli (adp-ribosa) polimerasas
ATE355278T1 (de) 2001-05-08 2006-03-15 Kudos Pharm Ltd Isochinolinon derivate als parp inhibitoren
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
TWI389897B (zh) 2005-02-22 2013-03-21 Chugai Pharmaceutical Co Ltd 1- (2H) -isoquinolinone derivatives
EP1904468A4 (en) * 2005-06-10 2009-04-22 Bipar Sciences Inc PARP MODULATORS AND TREATMENT OF CANCER
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
WO2008030887A2 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
AU2007292306A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
MX2009007831A (es) 2007-01-22 2010-01-15 Gtx Inc Agentes de union de receptor nuclear.
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
CA2676984C (en) 2007-02-01 2015-03-17 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
WO2009034326A1 (en) 2007-09-14 2009-03-19 Astrazeneca Ab Phthalazinone derivatives
UY31603A1 (es) 2008-01-23 2009-08-31 Derivados de ftalazinona
US8114995B2 (en) 2008-06-26 2012-02-14 Resverlogix Corp. Methods of preparing quinazolinone derivatives
CN102238945B (zh) 2008-10-07 2014-10-29 阿斯利康(英国)有限公司 药物制剂514
US8420668B2 (en) 2008-11-28 2013-04-16 Chugai Seiyaku Kabushiki Kaisha 1-(2H)-isoquinolone derivative
ES2542835T3 (es) 2009-01-08 2015-08-12 Resverlogix Corporation Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares
JP5795304B2 (ja) 2009-03-18 2015-10-14 レスバーロジックス コーポレイション 新規抗炎症剤
KR101892987B1 (ko) 2009-04-22 2018-08-30 리스버로직스 코퍼레이션 신규한 소염제
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
EP2935253B1 (en) 2012-12-21 2018-08-01 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
CA2977308A1 (en) 2015-03-13 2016-09-22 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0494231A4 (en) 1989-09-26 1992-09-16 The Regents Of The University Of California 6-amino-1,2-benzopyrones useful for treatment of viral diseases
US5484951A (en) 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5516941A (en) 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5473074A (en) 1991-10-22 1995-12-05 Octamer, Incorporated Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents-54
DE4436127A1 (de) 1994-09-27 1996-03-28 Deutsches Rheumaforschungszent Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen
WO1996031206A2 (en) * 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
US10766598B2 (en) 2017-06-14 2020-09-08 The Boeing Company Wing-to-fuselage joints and aircraft including the same

Also Published As

Publication number Publication date
AU7492698A (en) 1998-12-08
WO1998051307A1 (en) 1998-11-19
JP4362638B2 (ja) 2009-11-11
CN1261278A (zh) 2000-07-26
AU7484798A (en) 1998-12-08
WO1998051308A1 (en) 1998-11-19
AU745790B2 (en) 2002-03-28
EP1009404A4 (en) 2009-07-01
IL132758A0 (en) 2001-03-19
EP1009404A1 (en) 2000-06-21
JP2002502367A (ja) 2002-01-22
CA2289119C (en) 2011-03-15
BR9809115A (pt) 2002-01-02
CA2289119A1 (en) 1998-11-19
NZ501650A (en) 2001-11-30

Similar Documents

Publication Publication Date Title
CN1198614C (zh) pADPRT抑制剂在用于制备治疗炎症和炎性疾病的药物中的方法
US5908861A (en) Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
Tilg et al. Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Kamari et al. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice
Chan et al. Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis
Cantley et al. Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis
Lauzurica et al. Pyrrolidine dithiocarbamate protects mice from lethal shock induced by LPS or TNF‐α
Iyer et al. Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide
Busquets et al. Calpain-3 gene expression is decreased during experimental cancer cachexia
Ackland et al. Low-molecular-weight polyethylene glycol improves survival in experimental sepsis
Ma et al. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin in healthy and Vibrio alginolyticus‐infected large yellow croaker (Pseudosciaena crocea)
Kudva et al. Evaluation of the Stability, Bioavailability, and Hypersensitivity of the Omega-3 Derived Anti-Leukemic Prostaglandin: Δ12-Prostaglandin J3
Sirait et al. Profile of HMGB1 mRNA expression and TLR4 protein in BALB/c mice model sterile injury after systemic lidocaine administration
Wang et al. Combined transcriptomics and metabolomics analyses in grass carp under anesthetic stress
Brahn et al. Involution of collagen-induced arthritis with an angiogenesis inhibitor, PPI-2458
JPH10511345A (ja) 寄生生物および真菌感染処置のための組成物
Hill et al. Mechanisms of hepatic injury in alcoholic liver disease
Qu et al. Catechol compounds as dual-targeting agents for fish protection against Ichthyophthirius multifiliis infections
Motoki et al. Suppression of ischaemia‐induced cytokine release by dimaprit and amelioration of liver injury in rats
Yu et al. Characterization of caspase gene family in Sebastes schlegelii and their expression profiles under Aeromonas salmonicida and Vibrio anguillarum infection
Sjoerdsma Methyldopa.
Aleem et al. Perspective Chapter: Advances in the Development of Anti-Trichinella spiralis Vaccine, Challenges, and Future Prospective
Zumuk et al. Transmission-Blocking Vaccines against Schistosomiasis Japonica
Inaam et al. The effect of Haemonchus contortus infection and treatment with ivermectin on drug-metabolizing enzymes
US20230111232A1 (en) Pharmaceutical composition for preventing or treating rheumatoid arthritis and health functional food

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050427

Termination date: 20170513